Catalent (NYSE:CTLT) shares a gap up to $104.61


Catalent, Inc. (NYSE:CTLT – Get Rating) stock price rose ahead of Wednesday’s trading. The stock had previously closed at $104.61, but opened at $107.47. Catalent shares last traded at $104.04, with volume of 688 shares changing hands.

Several research analysts have commented on CTLT’s actions. Deutsche Bank Aktiengesellschaft cut its price target on Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a Tuesday, April 12 research report. StockNews.com began covering Catalent in a research report on Thursday, March 31. They issued a “holding” rating on the stock. Two equity research analysts gave the stock a hold rating and six gave the company a buy rating. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $142.86.

The company has a market capitalization of $17.96 billion, a PE ratio of 36.30, a growth price-earnings ratio of 1.62 and a beta of 1.32. The company has a debt ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The stock has a 50-day moving average price of $104.07 and a 200-day moving average price of $104.09.

Catalent (NYSE:CTLT – Get Rating) last announced its results on Tuesday, May 3. The company reported earnings per share (EPS) of $1.00 for the quarter, beating analyst consensus estimates of $0.89 by $0.11. Catalent had a return on equity of 15.07% and a net margin of 10.72%. The company posted revenue of $1.27 billion for the quarter, compared to analysts’ estimates of $1.22 billion. During the same period of the previous year, the company made earnings per share of $0.78. The company’s revenue for the quarter increased by 20.9% compared to the same quarter last year. As a group, equity research analysts predict Catalent, Inc. will post earnings per share of 3.57 for the current fiscal year.

Several hedge funds and other institutional investors have recently changed their positions in CTLT. Steph & Co. increased its stake in Catalent by 22.3% in the second quarter. Steph & Co. now owns 1,824 shares of the company valued at $196,000 after buying 333 additional shares in the last quarter. Private Advisor Group LLC increased its stake in Catalent to 98.5% in the second quarter. Private Advisor Group LLC now owns 5,870 shares of the company valued at $630,000 after buying 2,913 additional shares in the last quarter. ACG Wealth increased its holdings in Catalent by 9.6% in the second quarter. ACG Wealth now owns 33,605 shares of the company valued at $3,605,000 after purchasing an additional 2,940 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Catalent by 17.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,624 shares of the company valued at $1,354,000 after purchasing an additional 1,895 shares in the last quarter. Finally, Wedmont Private Capital increased its stake in Catalent by 56.5% in the second quarter. Wedmont Private Capital now owns 5,033 shares of the company valued at $540,000 after purchasing an additional 1,816 shares in the last quarter. 98.05% of the shares are currently held by institutional investors and hedge funds.

About Catalent (NYSE: CTLT)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for pharmaceuticals, protein biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Administration and Clinical Supply Services.

Recommended Stories



Get news and reviews for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Catalent and related companies with MarketBeat.com’s free daily email newsletter.

About Tina G.

Check Also

Tivity Health (NASDAQ:TVTY) receives new coverage from StockNews.com analysts

StockNews.com investment analysts have started covering stocks of Tivity Health (NASDAQ:TVTY – Get Note) in …